This idea gained traction with the findings that the loss of NLRC5 expression resulting from genetic and epigenetic causes is the most common mechanisms of MHC-I deficiency in cancers, and that loss of NLRC5 has poor prognosis for many cancers. The gene discussed is NLRC5; the disease is cancer.